Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016263 · ClinicalTrials.gov registry record · Phase 3
Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma
A Phase 3 study, sponsored by Genta Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00016263 is a Phase 3 study that has completed, run by Genta Incorporated.
The verdict
NCT00016263, a Phase 3 study, has completed, sponsored by Genta Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Oblimersen (G3139) may help dacarbazine kill more cancer cells by making tumor cells more sensitive to the drug. It is not yet known if dacarbazine is more effective with or without oblimersen (G3139). PURPOSE: Randomized phase III trial to compare the effectiveness of dacarbazine with or without oblimersen (G3139) in treating patients who have advanced malignant melanoma.
Interventions
- DRUG dacarbazine
- BIOLOGICAL oblimersen sodium
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-07 |
| Est. Completion | 2004-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00016263
The ClinicalTrials.gov registry entry for NCT00016263 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Genta Incorporated, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which dacarbazine is the first listed.
NCT00016263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00016263 about?
NCT00016263 is a clinical study titled "Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Oblimersen (G3139) may help dacarbazine kill more cancer cells by making tumor cells more sensitive to the drug. It is not yet known if dacarbazine is more effective with or withou...
What is the current status of trial NCT00016263?
This trial is currently completed. It is a Phase 3 study. The study started on 2000-07. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00016263?
The interventions under investigation include: dacarbazine (DRUG), oblimersen sodium (BIOLOGICAL).
Who is sponsoring clinical trial NCT00016263?
This trial is sponsored by Genta Incorporated, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.